Navigation Links
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
Date:6/2/2008

ave been treated with the second schedule, confirming the excellent safety profile of the drug. The dose escalation is still ongoing.

"Our recent data suggest, that intravenous infusion of AP 12009 is safe in patients suffering from malignant tumors, such as pancreatic carcinoma or melanoma. The survival data, observed in this Phase I/II study are very good, given the poor prognosis associated with these diseases," said Dr. Hubert Heinrichs, Chief Medical Officer of Antisense Pharma.

To further study the potential of the antisense treatment in pancreatic carcinoma, a Phase II study on AP 12009 in combination with the standard of care is scheduled to start in 2009. A Phase II study in malignant melanoma in combination with the current standard of treatment is currently being planned.

"The results of the Phase I/II study underscore again the high efficacy of AP 12009, which we have seen in high-grade glioma patients in the active-controlled Phase IIb study AP12009-G004. This study showed a strong survival benefit in patients treated with AP 12009 compared to standard chemotherapy treatment," commented Dr. Karl-Hermann Schlingensiepen, CEO of Antisense Pharma. "We have made huge progress in bringing the drug AP 12009 to patients with highly malignant tumors, who are in need of better therapies that prolong survival benefited by high quality of life."

Literature

(1) Hilbig, A. et al. "Systemic i.v. Administration of AP 12009: Preliminary Results of a Phase I/II Study in Pancreatic Carcinoma, Malignant Melanoma, or Colorectal Carcinoma", ASCO Annual Meeting, 2008, Abstract ID 4621

The Phase I/II study AP 12009-P001

In the open-label, multicenter, dose-escalation Phase I/II study, patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) repeatedly receive intravenous infusions of AP 12009. Primary study objective is to determine the maximu
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
2. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
3. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
11. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and HOUSTON, TX , Feb. ... "Company") (TSX-V: EPI) and Bloom Burton & Co. Ltd. ... voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares of ... Shares originally subject to the Lock-Up. Of the Common ... free trading immediately upon release from the Lock-Up while ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... Nev., Oct. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: ... 1, 2009 special dividend payment of $0.50 per share to ... 2009. , As previously announced, the conversion rate for ... was adjusted to 94.447 shares of common stock per $1,000 ...
... Service Corporation (CSC), the leader in Colorado Practice Management ... to be the exclusive provider of medical billing services ... thrilled to add this practice or our client list. ... is an endocrinology leader and pioneer. He is triple ...
Cached Medicine Technology:
(Date:2/28/2015)... AB (PRWEB) February 28, 2015 The ... is now a distributor of the machine. The Heart ... of their license, like a franchise model. The goal ... prevent and reverse heart disease. To buy External ... Fit Clinic can help individuals through this process and ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax accounting ... consulting services in addition to a variety of other ... planning. Company finances are a complicated matter that should ... this, complex Canadian tax laws can make it even ... Mew and Company works to advise their clients on ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Pioneer Millworks ... 2015 Japan Architecture & Construction Materials Show, an annual, ... more than 1,000 suppliers and top manufacturers of the ... Reclaimed wood products sourced and manufactured by Pioneer ... found popularity in Japan at restaurants, hotels, retailers, and ...
(Date:2/28/2015)... 28, 2015 India Network Foundation, ... visitor health insurance programs for visitors coming to the ... elderly parents traveling to the United States are suffering ... and blood pressure. These diseases are so common among ... them as medical conditions. There were 66.8 million cases ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
Statistics released by the Scottish Executive show that around 2.9 million clean needles were dispensed for drug users, but only 1.9 million were returned thus sparking a shortage of a million needles...
... become stagnant in our body result in Colon cancer. He received ... tissue cells can be damaged if the wastes are not removed ... cells become weak and unhealthy. One should have a bowel movement ... have shown that if you have a bowel movement every 3 ...
... Mouse population has been on the rise past two winters, ... field days for the scurrying mouse. Infact mouse proliferation has ... fallout of poor hygiene in mice habitats. ,Some ... fever, muscle aches, nausea, cough and abdominal pain, which surface ...
... it was appropriate for Rahul Mahajan to be taken to ... to Apollo hospital and not to AIIMS or Safdarjang even ... overdosing. //But medical experts say drug overdosed patients should be ... treated, the better are the chances of their survival. ...
... Melbourne University has launched a plan to improve the bedside ... effect, the medical students will be "embedded" with patients suffering ... two years. // ,This program will be compulsory ... Harvard Medical School in the US. "I think it would ...
... has been invited by non-resident Indians (NRIs) in Mauritius to tie ... be held June 18. // ,Ajeetpal Singh, who has a ... to tie 125 turbans or "safas" for a marriage ceremony. And ... hours. ,Singh plunged into this art at the age ...
Cached Medicine News:Health News:The myth about government hospitals 2
5L...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: